Osteoporos Int
-
Publication Venue For
- Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density.. 32:1217-1219. 2021
- Cost-effectiveness of balloon kyphoplasty and vertebroplasty versus conservative medical management in the USA.. 31:2461-2471. 2020
- How does women's bone health recover after lactation? A systematic review and meta-analysis.. 31:413-427. 2020
- Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.. 30:2019-2025. 2019
- Prognostic factors of in-hospital complications after hip fracture surgery: a scoping review.. 30:1339-1351. 2019
- Pre-discharge prognostic factors of physical function among older adults with hip fracture surgery: a systematic review.. 30:929-938. 2019
- Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community.. 30:507-511. 2019
- Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.. 30:45-57. 2019
- Response to Sabour: Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders: methodological issues.. 28:2261-2262. 2017
- The importance of physical function to people with osteoporosis.. 28:1597-1607. 2017
- Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders.. 28:925-934. 2017
- International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.. 28:767-774. 2017
- Risk factors for osteoporotic fractures in persons with spinal cord injuries and disorders.. 27:3011-3021. 2016
- Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.. 26:361-372. 2015
- The assessment of bone mineral content and density of the lumbar spine and proximal femur in US submariners.. 25:2225-2234. 2014
- Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function.. 25:1775-1784. 2014
- Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults.. 25:551-558. 2014
- Development of the Osteoporosis Assessment Questionnaire--physical Function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function.. 25:579-588. 2014
- Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.. 25:77-83. 2014
- Primary non-adherence to bisphosphonates in an integrated healthcare setting.. 24:2509-2517. 2013
- Morbidity following lower extremity fractures in men with spinal cord injury.. 24:2261-2267. 2013
- Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.. 24:2067-2077. 2013
- Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.. 24:263-269. 2013
- Frailty and sarcopenia: definitions and outcome parameters.. 23:1839-1848. 2012
- Measuring health-related quality of life (HRQOL) in osteoporotic males using the Male OPAQ.. 23:841-852. 2012
- Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.. 22:2539-2549. 2011
- Oral bisphosphonate compliance and persistence: a matter of choice?. 22:21-26. 2011
- Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.. 21:1021-1029. 2010
- Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.. 21:837-846. 2010
- The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).. 21:713-722. 2010
- Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research.. 20:1921-1927. 2009
- Determinants of 25-hydroxyvitamin D levels in African-American and Caucasian male veterans.. 20:1795-1803. 2009
- Effects of vitamin D insufficiency on bone mineral density in African American men.. 20:745-750. 2009
- Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.. 19:1247-1250. 2008